Janssen Global Services, LLC

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies (2023) Mcgonagle D, Mcinnes IBB, Deodhar A, Schett G, Shawi M, Chakravarty SDD, Kollmeier APP, et al. Journal article Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study (2023) Gerdes S, Hoffmann M, Asadullah K, Korge B, Mortazawi D, Krüger N, Personke Y, et al. Journal article Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance (2022) Simons G, Janssen EM, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Valor-Mendez L, et al. Journal article MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT) (2022) Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, et al. Journal article Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis (2022) Simons G, Bywall KS, Englbrecht M, Johansson EC, Disantostefano RL, Radawski C, Veldwijk J, et al. Journal article Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania (2022) Simons G, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Bywall KS, Mendez LV, et al. Journal article GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY (2022) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Cua D, et al. Conference contribution IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS (2022) Siebert S, Coates L, Schett G, Raychaudhuri SP, Chen W, Gao S, Chakravarty SD, et al. Conference contribution GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL (2022) Marzo-Ortega H, Theander E, Neuhold M, Bergmans P, Shawi M, Perate M, Contre C, et al. Conference contribution LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article